CLAIMS

1. A high dose extended-release potassium citrate tablet containing carnauba wax, which comprises: a first portion of melt- or heat-granulated potassium citrate and carnauba wax; and a second portion of non-granulated potassium citrate.

2. The ~~formulation~~ tablet according to Claim 1, wherein the high dose potassium citrate tablet contains more than 10-meq of potassium citrate.

3. The ~~formulation~~ tablet according to Claim 2, wherein the high dose potassium citrate tablet contains 15-meq of potassium citrate.

4. The ~~formulation~~ tablet according to Claim 1, wherein the non-granulated potassium citrate is 10-30% of the total amount of potassium citrate.

5. The ~~formulation~~ tablet according to Claim 4, wherein the non-granulated potassium citrate is 15-25% of the total amount of potassium citrate.

6. The ~~formulation~~ tablet according to Claim 1 wherein the carnauba wax in the melt- or heat-granulate is 7-25% of the total weight of the granulate.

7. The ~~formulation~~ tablet according to Claim 6, wherein the carnauba wax in the melt- or heat-granulate is 10-18% of the total weight of the granulate.

8. A 15-meq extended-release potassium citrate tablet, comprising a first portion of melt- or heat-granulated potassium citrate and carnauba wax; and a second portion of non-granulated potassium citrate, wherein the non-granulated potassium citrate comprises 15-25% of the total amount of potassium citrate, and wherein the melt- or heat-granulate contains 10-18% w/w of carnauba wax.

9. The ~~formulation~~ tablet according to Claim 8, which further comprises a lubricant.

10. The ~~formulation~~ tablet according to Claim 9, wherein the lubricant is magnesium stearate.

CLAIMS

1. A high dose extended-release potassium citrate tablet containing carnauba wax, which comprises: a first portion of melt- or heat-granulated potassium citrate and carnauba wax; and a second portion of non-granulated potassium citrate.

2. The tablet according to Claim 1, wherein the high dose potassium citrate tablet contains more than 10-meq of potassium citrate.

3. The tablet according to Claim 2, wherein the high dose potassium citrate tablet contains 15-meq of potassium citrate.

4. The tablet according to Claim 1, wherein the non-granulated potassium citrate is 10-30% of the total amount of potassium citrate.

5. The tablet according to Claim 4, wherein the non-granulated potassium citrate is 15-25% of the total amount of potassium citrate.

6. The tablet according to Claim 1 wherein the carnauba wax in the melt- or heat-granulate is 7-25% of the total weight of the granulate.

7. The tablet according to Claim 6, wherein the carnauba wax in the melt- or heat-granulate is 10-18% of the total weight of the granulate.

8. A 15-meq extended-release potassium citrate tablet, comprising a first portion of melt- or heat-granulated potassium citrate and carnauba wax; and a second portion of non-granulated potassium citrate, wherein the non-granulated potassium citrate comprises 15-25% of the

total amount of potassium citrate, and wherein the melt- or heat-granulate contains 10-18% w/w of carnauba wax.

9. The tablet according to Claim 8, which further comprises a lubricant.

10. The tablet according to Claim 9, wherein the lubricant is magnesium stearate.